Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration

Brain Research

Volumn 1140, Issue 1, 2007, Pages 188-194

  Kaur, Deepinder ^a   Rajagopalan, Subramanian ^a   Chinta, Shankar ^a   Kumar, Jyothi ^a   Di Monte, Donato ^b   Cherny, Robert A ^c   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b PARKINSON S INSTITUTE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aging; Dopamine; Ferritin; Iron chelation; Neurodegeneration; Parkinson's disease

Indexed keywords

DOPAMINE; FERRITIN;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FEMALE; IRON OVERLOAD; MALE; MESENCEPHALON; MOUSE; NERVE DEGENERATION; NERVE FIBER; NEURITE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; WHITE MATTER;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGE FACTORS; AGING; ANIMALS; DOPAMINE; EXPLORATORY BEHAVIOR; FERRITINS; GENE EXPRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NEURONS; ORGANIC CHEMICALS; SILVER STAINING; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

MURINAE;

EID: 33847677727     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.03.006     Document Type: Article

References (26)

1. Bartzokis G., Tishler T.A., Shin I.S., Lu P.H., and Cummings J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. N. Y. Acad. Sci. 1012 (2004) 224-236
2. Chen J.C., Hardy P.A., Kucharczyk W., Clauberg M., Joshi J.G., Vourlas A., Dhar M., and Henkelman R.M. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. Am. J. Neuroradiol. 14 (1993) 275-281
3. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., and LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65 (1995) 717-724
4. Crompton D.E., Chinnery P.F., Fey C., Curtis A.R., Morris C.M., Kierstan J., Burt A., Young F., Coulthard A., Curtis A., Ince P.G., Bates D., Jackson M.J., and Burn J. Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol. Diseases 29 (2002) 522-531
5. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., and Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28 (2001) 350-354
6. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., and Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 Pt. 4 (1991) 1953-1975
7. Double K.L., Maywald M., Schmittel M., Riederer P., and Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70 (1998) 2492-2499
8. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., Agid Y., and Hirsch E.C. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83 (2002) 320-330
9. Galy B., Ferring D., Minana B., Bell O., Janser H.G., Muckenthaler M., Schumann K., and Hentze M.W. Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood 106 (2005) 2580-2589
10. Griffiths P.D., Dobson B.R., Jones G.R., and Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122 Pt. 4 (1999) 667-673
11. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
12. Kienzl E., Puchinger L., Jellinger K., Linert W., Stachelberger H., and Jameson R.F. The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 134 (1995) 69-78
13. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Switzer III R., Grinberg A., Love P., Tresser N., and Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27 (2001) 209-214
14. Levi S., Cozzi A., and Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract. Res. Clin. Rheumatol. 18 (2005) 265-276
15. Linert W., Herlinger E., Jameson R.F., Kienzl E., Jellinger K., and Youdim M.B. Dopamine, 6-hydroxydopamine, iron, and dioxygen-Their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316 (1996) 160-168
16. Mancuso M., Davidzon G., Kurlan R.M., Tawil R., Bonilla E., Di Mauro S., and Powers J.M. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J. Neuropathol. Exp. Neurol. 64 (2005) 280-294
17. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., and Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36 (1994) 876-881
18. McCormack A.L., Atienza J.G., Johnston L.C., Andersen J.K., Vu S., and Di Monte D.A. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J. Neurochem. 93 (2005) 1030-1037
19. Monteiro H.P., and Winterbourn C.C. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38 (1989) 4177-4182
20. Peng J., Wu Z., Wu Y., Hsu M., Stevenson F.F., Boonplueang R., Roffler-Tarlov S.K., and Andersen J.K. Inhibition of caspases protects cerebellar granule cells of the weaver mouse from apoptosis and improves behavioral phenotype. J. Biol. Chem. 277 (2002) 44285-44291
21. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., and Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52 (1989) 515-520
22. Schmued L.C., and Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874 (2000) 123-130
23. Schmued L.C., Albertson C., and Slikker Jr. W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751 (1997) 37-46
24. Smith S.R., Cooperman S., Lavaute T., Tresser N., Ghosh M., Meyron-Holtz E., Land W., Ollivierre H., Jortner B., Switzer III R., Messing A., and Rouault T.A. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann. N. Y. Acad. Sci. 1012 (2004) 65-83
25. Thomas C.E., and Aust S.D. Reductive release of iron from ferritin by cation free radicals of paraquat and other bipyridyls. J. Biol. Chem. 261 (1986) 13064-13070
26. Vidal R., Ghetti B., Takao M., Brefel-Courbon C., Uro-Coste E., Glazier B.S., Siani V., Benson M.D., Calvas P., Miravalle L., Rascol O., and Delisle M.B. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 63 (2004) 363-380